Recent research reveals that obesity manifests in three distinct physiological forms, with differential responses to GLP-1 receptor agonists like Mounjaro. Individuals exhibiting naturally reduced gut hormone levels—particularly GLP-1—demonstrate significantly enhanced weight loss outcomes when treated with these medications, potentially achieving double the results compared to other obesity phenotypes. This discovery highlights the importance of personalized medicine approaches, suggesting that genetic and hormonal profiling could optimize treatment strategies and improve patient outcomes in weight management interventions.

Summary auto-generated by AI from the original publisher's content. Editorial standards.